Globally, few patients who need MDR-TB drugs actually get drugs of international quality. There are many identified barriers to getting lifesaving medicines to those who need them most.

  • Lack of support for detection, enrolment and treatment
  • Insufficient lab capacity
  • Inconsistent implementation of recommended treatment protocols
  • High drug prices as a result of small market
  • Lack of community awareness
  • Limited country and donor financing
  • Inconsistent tracking of patients
  • Majority of patients not offered international quality assured medicine
  • Complex in-country regulatory requirements and preferences
  • Low number of manufacturers who have attained internationally recognized quality standards
  • Lack of manufacturer incentives
  • Long lead times to satisfy orders
  • Variable in-country product supply chain management
  • Scarcity of supply chain-related data
  • Inadequate forecasting of future demand
  • New drugs not yet available in market

Overcoming the barriers

The partnership’s work in this area focuses on developing new thinking that can be translated to measureable action.

Second-line Drug Access Improvement Initiative

This initiative pulls together leading experts and stakeholders in the field to analyze bottlenecks to access, propose solutions and drive action so that people with MDR-TB have access to affordable, quality assured treatment.

Institute of Medicine Research Project

The Partnership supports the Institute of Medicine to assess the current status of scale-up efforts and vet new directions to improve access.

Innovation Summit

The Lilly MDR-TB Partnership and the Stop TB Partnership brought together 35 experts and innovators from multiple industries to create innovative solutions to help get internationally quality assured medicine to people in need. From 14 pre-identified barriers to MDR-TB drug supply, the group generated 90 potential solutions to second-line drug access. These solutions were grouped and developed into 12 achievable idea platforms with the strongest potential to create impact. Some of the 12 idea platforms are in the planning phase with partners. Others – in part or in full – had been also conceived by other organizations, and are being piloted around the world.